Literature DB >> 34668328

Trajectory mapping of primary Sjögren's syndrome via transcriptome learning demonstrates limitations of peripheral blood sequencing.

Bing Zhong1, Yaqiong Wang2, Qinghua Zou1, Chen Xuemeng1, Can Qian1, Chengshun Chen1, Jie Xiong3, Zihan Zheng4, Liyun Zou1,5, Jingyi Li1,4.   

Abstract

Primary Sjögren's syndrome (pSS) is a complex autoimmune disease characterized by aberrant immune cell action against secretory glands throughout the body. A number of studies have previously identified unique characteristics in the circulating expression profile of white blood cells of pSS patients. However, the molecular progression pattern of pSS is unclear. Through a systematic analysis of pSS transcriptome information, we found that pSS transcriptomes display broad heterogeneity, but cannot be distinguished from the broad range of possible profiles of healthy controls. Instead, only sample learning using a subset of pre-identified signature genes could achieve partial separation through a trajectory governed by interferon activity. Interestingly, this trajectory is correlated with a decrease in dendritic cell counts. Our study thus highlights a major limitation to the utility of broad blood transcriptome analysis in the context of pSS, while also identifying several factors that influence the divergence between patient samples.
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Sjögren's syndrome; trajectory mapping

Mesh:

Year:  2021        PMID: 34668328     DOI: 10.1111/1756-185X.14229

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  1 in total

1.  Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren's syndrome.

Authors:  Fan Xiao; Ke Rui; Man Han; Liyun Zou; Enyu Huang; Jie Tian; Lijun Zhang; Quan Jiang; Yuzhang Wu; Liwei Lu
Journal:  Signal Transduct Target Ther       Date:  2022-08-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.